Streetbeat News

PRE

Prenetics Global Limited

https://www.prenetics.com

Industry

Medical - Diagnostics & Research

Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

Open

4.42

Mkt cap

54M

Volume

418

High

4.42

P/E Ratio

-1.27

52-wk high

7.84

Low

4.42

Div yield

N/A

52-wk low

2.85

In Monday's after-market session, several health care stocks showed notable movements. GeneDx Holdings led the gainers with a 21.8% increase following their Q1 earnings release, while GlucoTrack experienced the largest decline among the losers, dropping 10.7%. Other notable movers included InnovAge Holding, Mustang Bio, and Vaxxinity, each responding to market dynamics and company-specific news.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 8:31 pm

Teledyne Technologies shares fell by 9% after reporting disappointing Q1 financial results and cutting FY24 EPS guidance. Other stocks showed significant movement, with notable gainers including Chicken Soup for the Soul Entertainment and BranchOut Food, and losers like Neo-Concept International and iSun.

Portfolio Pulse from Avi Kapoor

April 24, 2024 | 5:57 pm

Health care stocks showed significant movement in Wednesday's intraday session, with notable gainers including Catheter Precision, Prenetics Global, and Alterity Therapeutics, among others. On the downside, GlucoTrack, Evotec, and Vaxxinity led the losers, with Evotec and Addex Therapeutics specifically reacting to their Q4 earnings reports.

Portfolio Pulse from Benzinga Insights

April 24, 2024 | 4:31 pm

Cantor Fitzgerald analyst Ross Osborn maintains an Overweight rating on Prenetics Global (NASDAQ:PRE) but lowers the price target from $10 to $9.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 1:57 pm

Prenetics Global (NASDAQ:PRE) reported Q4 earnings with an EPS of $-0.51, beating estimates by 32.0% against an expected $-0.75. However, revenue declined by $46.89 million from the same period last year. Despite missing EPS estimates in Q3 2023, the share price increased by 0.0% the following day. The company's revenue has been fluctuating over the past quarters, with a notable drop in the most recent quarter compared to Q4 2022.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 1:55 pm

Prenetics Global (NASDAQ:PRE) reported Q4 adjusted EPS of $(0.51), surpassing the $(0.75) estimate, marking a significant decrease from last year's $1.30 per share. However, their quarterly sales of $5.43M fell short of the $17.60M estimate, despite being a 90.84% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 11:44 am

Healthcare stocks experienced significant movements in Tuesday's intraday session. Stoke Therapeutics (STOK) led the gainers with a 71.8% increase following their Q4 earnings report. Other notable gainers include Mesoblast (MESO), OpGen (OPGN), Alpha Teknova (TKNO), Nuvation Bio (NUVB), and Journey Medical (DERM). On the losing side, NeuBase Therapeutics (NBSE) saw the largest decline of 51.8%. Other decliners were Prenetics Global (PRE), Equillium (EQ), SCWorx (WORX), Monte Rosa Therapeutics (GLUE), and Biodexa Pharmaceuticals (BDRX).

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 5:31 pm

The article identifies five value stocks in the healthcare sector based on their low price-to-earnings (P/E) multiples, suggesting they may be undervalued. The stocks mentioned are Cross Country Healthcare (CCRN), Prenetics Global (PRE), Spero Therapeutics (SPRO), Arcturus Therapeutics (ARCT), and Zymeworks (ZYME). The article also provides recent changes in earnings per share for these companies and notes the risks associated with investing in value stocks.

Portfolio Pulse from Benzinga Insights

December 04, 2023 | 2:44 pm

The article identifies notable value stocks in the healthcare sector based on low P/E multiples, suggesting they may be undervalued. Nuwellis, Exicure, Acorda Therapeutics, Prenetics Global, and Ocuphire Pharma are mentioned with their respective P/E ratios and recent earnings per share (EPS) data. The article highlights the potential for value stocks to rebound but also notes the risk that the expected emergence may not materialize.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 2:44 pm

Prenetics Global (NASDAQ:PRE) reported Q3 EPS of $(0.05), surpassing the $(0.06) estimate, but experienced a significant decrease from last year's $0.30 per share. Quarterly sales were $4.87M, falling short of the $18.14M estimate, yet marking a 13.29% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 11:12 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.